Patient Dosing Resumes in Alzheimer’s Clinical Trial

Patient Dosing Resumes in Alzheimer’s Clinical Trial

By: Tomas Ronolski - News

Thursday, January 20, 2022

Treatments for Alzheimer’s continue to be lacking in the clinical community. A drug repurposing by the pharmaceutical company has the potential to be an effective treatment for mild to moderate AD.

After a delay due to the global pandemic, leading drug delivery company IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) has resumed patient dosing in the ongoing Phase 2a (“BUENA”) clinical trial. Under the previously amended protocol, higher doses of Montelukast VersaFilm are used in patients with mild to moderate Alzheimer’s Disease, per the company’s press release.

IntelGenx management believes that the treatment has the potential to modify treatment of the disease. 

Shares were trading up at $0.44 in afternoon trade. 

Copyright © 2021 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Improving Air Safety and Disrupting the Air Treatment Industry
Walking the Walk, This Penny Stock Crushing It In 2022
Leading Cannabis Accessory Distributor Announces Q3 Results and Rapid Expansion into California
Most Popular
FREE Newsletter Favorites

Back to Top